In the context of hematological malignancies, ~2% of acute myeloid leukemia patients have a 9q21.32 deletion that encompasses the HNRNPK gene, resulting in loss of one copy of HNRNPK. Consequently, haploinsufficiency of HNRNPK was shown to be pathogenic in mice, as an Hnrnpk+/- mouse model showed a myeloproliferative phenotype and reduced survival. Here, HNRNPK is linked to hematologic disorder.